Seer's core business model is centered on an integrated proteomics platform combining hardware, consumables, and services, which is well-differentiated in enabling population-scale proteomics studies. The hybrid product-service revenue model and strategic partnerships provide competitive moats, alt…
Seer (SEER) Q1 2025: 37% Revenue Growth Driven by Population-Scale Proteomics Momentum
Seer’s Q1 revenue surged 37% year-over-year, propelled by accelerated instrument shipments and expanding service projects despite macroeconomic headwinds. The company’s pioneering Proteograph platform is gaining traction with large-scale proteomics studies, signaling a shift toward population-scale biological data generation. Management maintains full-year guidance amid cautious monitoring of funding and tariff risks.
Summary
- Population-Scale Proteomics Adoption: Seer is driving a new paradigm with large cohort studies enabled by its Proteograph product suite.
- Operational Expansion: STAC service growth and instrument shipment acceleration indicate strengthening customer engagement and platform validation.
- Strategic Resilience: Strong cash position and disciplined cost management underpin confidence despite ongoing macroeconomic and policy uncertainties.
Business Overview
Seer operates in the life sciences sector, commercializing the Proteograph Product Suite, an integrated proteomics platform that combines engineered nanoparticles, consumables, automation instrumentation, and software to perform deep, unbiased proteomic analyses at scale. The company generates revenue primarily through product sales of instruments and consumables, alongside service revenue from its Seer Technology Access Center (STAC), which offers proteomics services to customers. Its customer base spans academic, government, and biopharma sectors.
Performance Analysis
Seer reported first quarter 2025 revenue of $4.2 million, up 37% from $3.1 million in Q1 2024, driven by increased instrument shipments and service revenue. Product revenue accounted for $2.9 million, reflecting sales of Proteograph instruments and consumables, while service revenue rose to $1.2 million, primarily from STAC projects. Gross margin improved to 49% from 44% a year ago, reflecting a higher proportion of service revenue, though management anticipates quarterly variability as revenue mix fluctuates.
Operating expenses declined 14% year-over-year to $22.8 million, led by reductions in stock-based compensation and laboratory costs. Research and development expenses fell 7%, and selling, general, and administrative expenses decreased 20%. Despite these efficiencies, net loss remained substantial at $19.9 million, reflecting ongoing investments in innovation and growth. The company ended the quarter with approximately $285 million in cash, cash equivalents, and investments, underscoring a strong liquidity position.
- Revenue Growth Concentrated in Product and Service Mix: Instrument shipments in Q1 matched full-year 2024 levels, while STAC service volumes expanded, indicating growing platform adoption.
- Cost Discipline Enhances Operating Leverage: Lower stock-based compensation and lab expenses contributed to reduced operating costs despite investment in R&D.
- Cash Reserves Support Strategic Flexibility: The sizable cash position provides runway to pursue innovation and weather macroeconomic uncertainties.
Overall, Seer demonstrated solid execution in scaling its proteomics platform, balancing growth with prudent cost management amid a challenging funding and policy environment.
Executive Commentary
"We shipped as many instruments in the first quarter of 2025 as we did in all of 2024 and saw continued traction for SEER Technology Access Center, or STAC. Our customers are discovering novel biology that will solve challenges in human health, growing existing end markets that leverage proteomics, and creating entirely new end markets that do not exist today."
Omid Farokhzad, Chief Executive Officer and Chair of the Board
"We continue to expect overall volatility in our gross margins on a quarterly basis. At scale, we continue to believe our long-term gross margins will be in the range of 70% to 75%. We ended the quarter with approximately $285 million in cash, cash equivalents, and investments. Importantly, we believe that with our current cash, cash equivalents, and investments on hand, we have sufficient capital to reach cash flow breakeven."
David Horn, Chief Financial Officer and President
Strategic Positioning
1. Accelerating Population-Scale Proteomics Studies
Seer is pioneering large cohort proteomic analyses, exemplified by a landmark 10,000-sample study conducted in collaboration with Discovery Life Sciences and a new customer. This project underscores the platform's capability to generate unprecedented biological insights at scale and is expected to unfold over 12 to 18 months. Management anticipates additional large-scale studies, signaling a strategic shift toward population-scale proteomics akin to genomics' trajectory.
2. Expanding Access via STAC and Instrument Placement
The Seer Technology Access Center (STAC) continues to lower adoption barriers by allowing customers to run proteomics projects without immediate instrument purchases. Q1 saw half of instrument shipments going to prior STAC users, marking the highest conversion rate to in-house instruments. The Strategic Instrument Placement Program (SIP) further supports customers facing capital constraints, enhancing adoption amid macroeconomic pressures.
3. Strengthening Commercial Partnerships
Seer’s expanded collaboration with Thermo Fisher Scientific integrates the Proteograph product suite with the Orbitrap Astral mass spectrometer, offering a robust end-to-end solution. Training of Thermo Fisher’s US and European sales forces is underway, with early traction in multiple regions. This partnership broadens Seer’s commercial reach and facilitates customer access to scalable proteomics solutions.
4. Innovating Product Capabilities
Seer continues to enhance the Proteograph platform’s versatility, recently launching the CellLifed application to extend analysis beyond plasma and tissue to diverse sample types including cerebrospinal fluid and dry blood spots. The company plans ongoing protocol expansions to meet varied research needs, reinforcing its commitment to product innovation as a growth driver.
5. Proactive Margin and Supply Chain Management
In response to newly introduced tariffs and supply chain uncertainties, Seer has secured price stability agreements with suppliers for the near term and is evaluating cost structure improvements to enhance margins. While no direct supply disruptions have occurred, the company remains vigilant amid evolving trade policies, especially regarding international sales exposure.
Key Considerations
Seer’s first quarter results reflect strategic execution amid a dynamic macro environment characterized by government funding uncertainties and tariff-related risks. The company’s emphasis on population-scale projects and expanding customer access positions it well for long-term growth, but near-term visibility remains limited.
Key Considerations:
- Macroeconomic Headwinds: Ongoing government funding volatility and tariff policies create uncertainty in customer spending and international revenue.
- Revenue Mix Volatility: Fluctuations between product and service revenue drive gross margin variability quarter-to-quarter.
- Capital Allocation Discipline: Continued share repurchases and cautious R&D spending reflect management’s focus on shareholder value and sustainable growth.
- Customer Base Diversification: Balanced revenue from academic, government, and biopharma sectors provides some insulation but also exposure to shifting funding landscapes.
- Scaling Operational Capacity: Enhancements in STAC capacity and instrument placement programs will be critical to sustaining adoption momentum.
Risks
Seer faces risks from potential reductions in NIH and government research funding that could dampen demand from academic and government customers, which represent approximately 30% of revenue. Tariff implementations and evolving trade policies may impact supply chain costs and international sales, particularly in China. The company’s net losses and cash burn, while currently supported by a strong balance sheet, require careful management amid uncertain macroeconomic conditions.
Forward Outlook
For the second quarter of 2025, Seer expects continued revenue growth supported by instrument shipments and STAC service projects, though acknowledges potential variability due to macroeconomic factors. Management reaffirmed full-year 2025 revenue guidance of $17 to $18 million, reflecting 24% growth at the midpoint over 2024.
- Full-year revenue guidance maintained at $17 to $18 million, with cautious assumptions on customer budget pressures and funding uncertainty.
- Gross margin expected to remain variable quarter-to-quarter, with long-term target margins of 70% to 75%.
Management highlighted ongoing monitoring of tariff impacts and government funding developments, with a focus on operational efficiencies and strategic investments to drive sustained growth.
Takeaways
Seer’s Q1 performance underscores the company’s pioneering role in enabling large-scale proteomics studies, a critical inflection point for the sector. The combination of technology validation, expanding service offerings, and strategic partnerships positions Seer to capitalize on growing demand for deep biological insights at scale.
- Growth Engine: The 10,000-sample study and increasing STAC-to-instrument conversions illustrate accelerating adoption and platform validation.
- Strategic Balance: Management’s disciplined cost control and strong cash reserves provide flexibility to navigate macro uncertainties while investing in innovation.
- Forward Focus: Investors should monitor the evolution of government funding, tariff impacts, and the pace of large cohort study announcements as key indicators of future momentum.
Conclusion
Seer delivered robust revenue growth and operational progress in Q1 2025, driven by its Proteograph platform’s expanding footprint in population-scale proteomics. While macroeconomic and policy uncertainties temper near-term visibility, the company’s strategic initiatives and strong financial position provide a solid foundation for sustained advancement in the proteomics market.
Industry Read-Through
Seer’s results highlight a broader industry trend toward scaling proteomics to population levels, mirroring genomics’ past evolution. The emphasis on large cohort studies and integrated service models signals a maturing market where deep biological data generation becomes more accessible. Other life sciences companies should note the critical role of strategic partnerships, platform versatility, and customer access programs in driving adoption amid funding and policy challenges. The company’s navigation of tariff-related risks also offers a cautionary lens for peers with international exposure.